- New
-
Topics
- All Categories
- Metaphysics and Epistemology
- Value Theory
- Science, Logic, and Mathematics
- Science, Logic, and Mathematics
- Logic and Philosophy of Logic
- Philosophy of Biology
- Philosophy of Cognitive Science
- Philosophy of Computing and Information
- Philosophy of Mathematics
- Philosophy of Physical Science
- Philosophy of Social Science
- Philosophy of Probability
- General Philosophy of Science
- Philosophy of Science, Misc
- History of Western Philosophy
- Philosophical Traditions
- Philosophy, Misc
- Other Academic Areas
- Journals
- Submit material
- More
Assessing risk/benefit for trials using preclinical evidence: a proposal
Journal of Medical Ethics 42 (1):50-53 (2016)
Abstract
This article has no associated abstract. (fix it)Links
PhilArchive
External links
(no proxy)
Setup an account with your affiliations in order to access resources via your University's proxy server
Through your library
- Sign in / register and customize your OpenURL resolver
- Configure custom resolver
My notes
Similar books and articles
Stopping trials early for commercial reasons: the risk-benefit relationship as a moral compass.A. S. Iltis - 2005 - Journal of Medical Ethics 31 (7):410-414.
Ethical Issues in Cancer Chemoprevention Trials: Considerations for IRBs and Investigators.Julia Slutsman, David Buchanan & Christine Grady - 2007 - IRB: Ethics & Human Research 29 (2):1-6.
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.Jonathan Kimmelman & Alex John London - unknown
The Risk-Escalation Model: A Principled Design Strategy for Early-Phase Trials.Spencer Phillips Hey & Jonathan Kimmelman - 2014 - Kennedy Institute of Ethics Journal 24 (2):121-139.
Launching Invasive, First-in-Human Trials Against Parkinson’s Disease: Ethical Considerations.Jonathan Kimmelman, Alex John London, Bernard Ravina, Tim Ramsay, Mark Bernstein, Alan Fine, Frank W. Stahnisch & Marina Elena Emborg - unknown
Evaluating the Risks and Benefits of Phase II and III Clinical Cancer Trials: A Look at Institutional Review Board Members in the Netherlands.H. van Luijn, A. Musschenga, R. Keus & N. Aaronson - 2007 - IRB: Ethics & Human Research 29 (1).
A call to restructure the drug development process: Government over-regulation and non-innovative late stage (phase III) clinical trials are major obstacles to advances in health care.Thomas C. Jones - 2005 - Science and Engineering Ethics 11 (4):575-587.
The risk-benefit task of research ethics committees: An evaluation of current approaches and the need to incorporate decision studies methods. [REVIEW]Johannes J. M. Van Delden Rosemarie D. L. C. Bernabe, Ghislaine J. M. W. Van Thiel, Jan A. M. Raaijmakers - 2012 - BMC Medical Ethics 13 (1):6.
Ethical reflections on clinical trials with human tissue engineered products.L. Trommelmans, J. Selling & K. Dierickx - 2008 - Journal of Medical Ethics 34 (9):e1-e1.
Prudent Precaution in Clinical Trials of Nanomedicines.Gary E. Marchant & Rachel A. Lindor - 2012 - Journal of Law, Medicine and Ethics 40 (4):831-840.
Are Phase 1 Trials Therapeutic? Risk, Ethics, and Division of Labor.James A. Anderson & Jonathan Kimmelman - 2012 - Bioethics 28 (3):138-146.
Pascal’s Wager, Infective Endocarditis and the “No-lose” Philosophy in Medicine.David Shaw & David Conway - 2010 - Heart 96 (1):15-18.
How to take deontological concerns seriously in risk-cost-benefit analysis: a re-interpretation of the precautionary principle.S. D. John - 2007 - Journal of Medical Ethics 33 (4):221-224.
The harm-benefit tradeoff in "bad deal" trials.Gillian Nycum & Lynette Reid - 2007 - Kennedy Institute of Ethics Journal 17 (4):321-350.
Strengthening the ethical assessment of placebo-controlled surgical trials: three proposals.Wendy Rogers, Katrina Hutchison, Zoë C. Skea & Marion K. Campbell - 2014 - BMC Medical Ethics 15 (1):78.
Analytics
Added to PP
2016-02-04
Downloads
38 (#397,063)
6 months
3 (#880,460)
2016-02-04
Downloads
38 (#397,063)
6 months
3 (#880,460)
Historical graph of downloads
Citations of this work
Do we really know how many clinical trials are conducted ethically? Why research ethics committee review practices need to be strengthened and initial steps we could take to strengthen them.Mark Yarborough - 2021 - Journal of Medical Ethics 47 (8):572-579.
Epigenetics Changes Nothing: What a New Scientific Field Does and Does Not Mean for Ethics and Social Justice.Jonathan Y. Huang & Nicholas B. King - 2018 - Public Health Ethics 11 (1):69-81.
Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic.Emilie Alirol, Annette C. Kuesel, Maria Magdalena Guraiib, Vânia Dela Fuente-Núñez, Abha Saxena & Melba F. Gomes - 2017 - BMC Medical Ethics 18 (1):43.
Rescuing Informed Consent: How the new “Key Information” and “Reasonable Person” Provisions in the Revised U.S. Common Rule open the door to long Overdue Informed Consent Disclosure Improvements and why we need to walk Through that door.Mark Yarborough - 2020 - Science and Engineering Ethics 26 (3):1423-1443.
Erratum to: Ethics review of studies during public health emergencies - the experience of the WHO ethics review committee during the Ebola virus disease epidemic.Emilie Alirol, Annette C. Kuesel, Maria Magdalena Guraiib, Vânia de la Fuente-Núñez, Abha Saxena & Melba F. Gomes - 2017 - BMC Medical Ethics 18 (1):45.
References found in this work
Predicting harms and benefits in translational trials: ethics, evidence, and uncertainty.Jonathan Kimmelman & Alex John London - unknown
The social value of clinical research.Michelle Gjl Habets, Johannes Jm van Delden & AnneLien L. Bredenoord - 2014 - BMC Medical Ethics 15 (1):66.
Building an Ethical Foundation for First-in-Human Nanotrials.Rebecca Dresser - 2012 - Journal of Law, Medicine and Ethics 40 (4):802-808.
Building an Ethical Foundation for First-in-Human Nanotrials.Rebecca Dresser - 2012 - Journal of Law, Medicine and Ethics 40 (4):802-808.
Extending Clinical Equipoise to Phase 1 Trials Involving Patients: Unresolved Problems.James A. Anderson & Jonathan Kimmelman - 2010 - Kennedy Institute of Ethics Journal 20 (1):75-98.
PhilPapers logo by Andrea Andrews and Meghan Driscoll.
This site uses cookies and Google Analytics (see our terms & conditions for details regarding the privacy implications). Use of this site is subject to terms & conditions.
All rights reserved by The PhilPapers Foundation
Server: philpapers-web-6d9b7f7c4c-sqt28 uwo